Table 1 Demographic and clinical data of the study population

Current age, years, mean (SD)

15.2 (± 2)

Level of education (ISCED)^a n (%)

ISCED 2: 6 (19.4)

ISCED 3–5: 25 (80.6)

Extracurricular activities n (%)

9 (29,0%)

Duration of disease, years in T, mean (SD)

2.7 (± 2.7)

Age at diagnosis, years, mean (SD)

12.7 (± 3.4)

Time to diagnosis, months, mean (SD)

4.9 (± 3.6)

Paris age n (%)

A1a 7 (22,6%)/A1b 24 (77,4%)

Paris location n (%)

 L1 (Distal 1/3 ileal + limited cecal disease): 1 (3,2%)

 L2 (Colonic): 3 8 (9,6%)

 L3 (Ileocolonic): 18 (58,1%)

 L3L4a (Ileocolonic + Upper discase proximal to Ligament of Treitz):8 (25,9%)

 L2L4a (Colonic + Upper discase proximal to Ligament of Treitz): 1 (3,2%)

Paris phenotype n (%)

 B1 (nonstricturing nonpenetrating): 27 (87,1%)

 B2 (Stricturing): 3 (9,7%)

 B3 (Penetrating): 1 (3,3%)

 Perianal disease 5 (16,1%)

Paris growth n (%)

 G0 (No evidence of growth delay): 27 (87,1%)

 G1 (Growth delay): 4 (12,9)

PCDAI at diagnosis, mean (SD)^b

36,3 (25; 51,3)

 Inactive disease (PCDAI 0–12,5): 4 (12,9%)

 Mild to moderate disease (12,5–32,5): 10 (32,3%)

 Moderate to severe disease (> 32,5): 17 (54,8%)

Need of admission at diagnosis n (%)

21 (67,7%)

Induction treatment n (%)

TEN^c 20 (64,5%)

PDN^d 9 (29%)

Anti TNF alfa^e 2 (6,5%)

Current treatment n (%)

Immunomodulator 15 (48,4%)

Immunomodulator + EN d1(3,2%)

Immunomodulator + PDN^d2 (6,5%)

Anti TNF alfa^e 13 (41,9%)

Need of surgery at diagnosis (%)

7 (22,6%)

Number of biological until recruitment n/31 (%)

11/31 (35,5%) 1

3/11 (9,7%) 2

Need for hospitalization in the prior 6 months n (%)

3 (9,7%)

Need for surgery in the prior 6 months n (%)

0 (0%)

Treatment modifications n (%)^f

3(9,7%

Need for corticosteroids in the prior 6 months n (%)

2 (6,5%)

Poor compliance to treatment in the prior 6 months n (%)^f

3 (9,7%)